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Ocular herpes simplex virus type 1 (HSV-1) infection of MHC-II-deficient mice (Ab
O/O mice) or their parental C57BL/6J
wild-type mice resulted in the establishment of typical HSV-1 latent infections in the trigeminal ganglia (TG) of the surviving
mice by day 28 postinfection. Latency was characterized by the complete absence of infectious virus in TG extracts, the
ability to recover latent virus only following prolonged tissue culture cultivation of explanted TG, and the presence of HSV-1
DNA in TG extracts. When mice were vaccinated prior to ocular HSV-1 challenge, latency appeared unaltered in the C57BL/6J
wild-type mice. However, in Ab
O/O mice, clearance of virus from the TG appeared to be seriously impaired, resulting in a
chronic productive infection, rather than a latent infection. Infectious virus was readily detected in TG extracts of vaccinated
Ab
O/O mice until at least 63 days postinfection. Glycoprotein B mRNA was also readily detected, confirming continued viral
transcription. These chronic infections occurred regardless of whether the Ab
O/O mice were vaccinated with HSV-1-specific
antigens (i.e., live HSV-1 strain KOS, recombinantly expressed HSV-1 glycoprotein D plus Freund’s adjuvant, or a mixture of
seven recombinantly expressed HSV-1 glycoproteins plus adjuvant) or non-HSV-1-specific antigens (i.e., tissue culture
medium plus 5% fetal bovine serum, the expression vector plus adjuvant, or adjuvant alone). Passive transfer of HSV-1
neutralizing antibody to vaccinated Ab
O/O mice between days 0 and 28 post-ocular challenge did not clear infectious virus from
the TG. Passive transfer of anti-HSV-1 antibody or purified naive mouse serum to unvaccinated Ab
O/O mice on days 3 or 6
post-HSV-1 ocular challenge also resulted in chronic, rather than latent, infection of the TG. Passive transfer of naive sera
from B-cell-deficient mice or injection of keyhole limpet hemocyanin or purified IgG, but not PBS or dextran, 3 days after
HSV-1 challenge also resulted in chronic infection of the TG. © 1999 Academic Press
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HINTRODUCTION
Persistent viral infections can be divided into at least two
ategories, chronic (productive) infections and latent (non-
roductive) infections (Buchmeier et al., 1980; Haywood,
986; Marion and Robinson, 1983). In chronic infections,
nfectious virus is present and can be detected by standard
irological methods. Hepatitis B infections in humans and
CMV infections in mice are classic examples (Ahmed et
l., 1987; Jamieson and Ahmed, 1989; Marion and Robinson,
983). In latent infections, the viral genome is present and
ersists throughout the life of the infected individual, but
here is no detectable infectious virus except during inter-
ittent episodes of reactivation. Herpes simplex virus type
(HSV-1) and HSV-2 infections in humans and in animal
odels including the mouse are classic examples (Cook et
l., 1974; Jordan et al., 1984; Rock et al., 1987; Wechsler et
l., 1988b).
1 To whom correspondence and reprint requests should be ad-
ressed at Ophthalmology Research, Davis Building, Room 5072, Ce-
ars-Sinai Research Institute, 8700 Beverly Boulevard, Los Angeles, CA
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208Following primary ocular HSV-1 infection, the immune
ystem of naive wild-type mice clears all infectious virus
rom the animal within 2 weeks (Fraser et al., 1991;
hiasi et al., 1996; Stevens, 1978). Infectious virus is also
leared from neuronal cells; however, in these cells,
SV-1 establishes a latent infection (Cook et al., 1974;
echsler et al., 1988a). During HSV neuronal latency,
here is an absence of viral proteins and infectious virus,
nd LAT (latency-associated transcript) is the only gene
roduct consistently detected in abundance (Rock et al.,
987; Wechsler et al., 1988b).
In wild-type mice, latency can be altered (i.e., reduced)
y vaccination or passive transfer of anti-HSV-1 antibody
Ghiasi et al., 1994; Lausch et al., 1990). Thus, if mice are
accinated with a highly efficacious vaccine and then
cularly challenged with HSV-1, or if mice receive HSV-1
eutralizing antibody prior to or very early after infection,
atent virus is recovered from fewer or even no trigeminal
anglia (TG), following explant cocultivation. Thus, vac-
ination or passive transfer of anti-HSV-1 antibody can
reatly reduce, or even prevent, the establishment of
SV-1 latency.
The original goal of the present study was to deter-
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209CHRONIC HSV-1 INFECTION IN Ab
O/O MICEine whether HSV-1 latency was altered in naive or
accinated mice deficient for MHC-II (Ab
O/O mice). This
as of interest, because in previous studies we noticed
hat some of the vaccinated Ab
O/O mice appeared to die
ater than expected (unpublished observations). Since
urvival is routinely measured on day 28 postinfection,
nd since this apparent variance in time of death did not
each statistical significance, we have not previously
eported this observation (Ghiasi et al., 1997a). Thus,
hile those HSV-1 ocularly challenged naive and vacci-
ated wild-type mice and those naive Ab
O/O mice that died
rom the HSV-1 infection all did so by day 14 postinfec-
ion, some of the vaccinated Ab
O/O mice died as late as 24
ays postinfection. In additional experiments with vacci-
ated, but not naive, Ab
O/O mice, we have occasionally
bserved virus-induced death after day 28, a time at
hich only latent virus should be present. Since reacti-
ation of HSV-1 in mice is extremely rare, this observa-
ion suggested that the clearance of virus from the tri-
eminal ganglia of vaccinated Ab
O/O mice may have been
efective.
We report here that vaccination of Ab
O/O mice appeared
o somehow interfere with clearance of HSV-1 following
cular challenge. A chronic, rather than a latent, infection
ppeared to develop in the TG of these mice. This
hronic infection was confirmed by (a) the presence of
nfectious virus in the supernatant of homogenized tri-
eminal ganglia and (b) detection of viral mRNA by RT-
CR of trigeminal ganglia extracts. Additional studies
evealed that: (1) passive transfer of anti-HSV-1 antibody
id not clear the virus; (2) passive transfer of antibody to
nvaccinated Ab
O/O mice on day 3 or 6 post-ocular chal-
enge resulted in chronic infections similar to those seen
n vaccinated Ab
O/O mice; (3) passive transfer of sera from
cell-deficient mice or injection of KLH or IgG also
esulted in chronic infections; and (4) challenge of Ab
O/O
ice 12 weeks rather than 3 weeks postvaccination
esulted in less chronic infection.
RESULTS
Detection of infectious virus in cell-free extracts of
rigeminal ganglia from Ab
O/O mice that were vaccinated
rior to ocular challenge. To determine whether vaccina-
ion of Ab
O/O mice, which lack both MHC-II and CD41
-cells (Cosgrove et al., 1991), alters latency following
cular challenge with HSV-1, groups of Ab
O/O and their
arental wild-type C57BL/6J mice were vaccinated three
imes with various vaccines and then challenged ocu-
arly with HSV-1. A group of b2m
O/O mice, which lack
HC-I and have reduced levels of CD81 T-cells (Koller et
l., 1990; Koller and Smithies, 1989), were also included
s a control. The vaccines consisted of (1) live KOS (a
onvirulent HSV-1 strain); (2) MEM 1 5% fetal bovine
erum (MEM), a control for the KOS vaccine; (3) baculo-
irus expressed HSV-1 glycoprotein D (gD) plus Freund’s pdjuvant; (4) a mixture of seven expressed HSV-1 glyco-
roteins (7gp); (5) wild-type (wt) baculovirus plus
reund’s adjuvant (vector), a control for the recombinant
D and seven glycoprotein vaccines; (6) PBS 1 Freund’s
djuvant; (7) Freund’s adjuvant alone; or (8) not vacci-
ated with anything (age-matched unvaccinated mice),
s described under Materials and Methods.
Mice surviving ocular challenge were euthanized on
ay 28 or day 31 postinfection. The left TG from each
ouse was freeze–thawed and homogenized as de-
cribed under Materials and Methods. This destroys all
iable cells. Any infectious virus detected in these ex-
racts therefore represents infectious virus that was
resent in the TG at the time of sacrifice, since detection
f latent virus requires the explant cultivation of intact,
ive neurons (Cook et al., 1974; Jordan et al., 1984). As
xpected, none of the TGs from vaccinated or unvacci-
ated b2m
O/O or wild-type C57BL/6J mice contained any
nfectious virus at the time of sacrifice (Table 1, columns
to 8). This was true regardless of the vaccine. In
ontrast, as expected, explant cocultivation of the right
Gs from the same vaccinated and unvaccinated b2m
O/O
ice and C57BL/6J mice revealed that 85–100% of these
Gs harbored latent HSV-1 (data not shown).
Only 1 of 52 TGs from unvaccinated (naive) Ab
O/O mice
ontained infectious virus at the time of sacrifice (Table
, column 2). In contrast, 69–100% of the TGs from Ab
O/O
ice vaccinated with different agents contained infec-
ious virus (Table 1, columns 3–8). Overall, 92% (158 of
71) of the TGs from vaccinated Ab
O/O mice contained
nfectious virus. Thus, in sharp contrast to the majority of
Gs from unvaccinated Ab
O/O mice and vaccinated and
nvaccinated b2m
O/O mice and C57BL/6J mice, which
ppeared to contain latent virus and no infectious virus,
he vast majority of TGs from vaccinated Ab
O/O mice con-
ained infectious virus.
These results strongly suggest that vaccination of Ab
O/O
ice prior to ocular challenge with HSV-1 impaired clear-
nce of HSV-1 from TGs and resulted in a chronic rather
han a latent infection in the majority of TGs. This ap-
eared to occur regardless of whether vaccination was
one with HSV-1-specific or nonspecific antigens. Thus,
accination with live HSV-1 or recombinantly expressed
SV-1 glycoproteins, vaccination with adjuvant alone,
nd even vaccination with tissue culture medium con-
aining 5% fetal calf serum all resulted in chronic, rather
han latent, infections of the TG.
As indicated above, almost all of the right TGs from the
nvaccinated Ab
O/O mice and the vaccinated and unvac-
inated b2m
O/O and C57BL/6J mice contained latent
SV-1 as judged by explant cultivation. Thus, it is logical
o assume that most of the left TGs from these mice, from
hich infectious virus was not detected, were also la-
ently infected. To confirm this, DNA was isolated from
ome of the disrupted cell pellets and tested for the
resence of HSV-1 DNA by PCR using HSV-1-specific
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210 GHIASI ET AL.rimers. Almost all of the TGs from unvaccinated Ab
O/O
ice (35 of 36) and vaccinated and unvaccinated b2m
O/O
ice (49 of 50) and wild-type C57BL/6J mice (54 of 57)
ontained HSV-1 DNA and therefore were latently in-
ected (data not shown). HSV-1 DNA was also present in
he TG debris from vaccinated Ab
O/O mice; however, it is
ot known whether this DNA was from infectious virus
nly, whether some of the neurons in these TGs were
atently infected, or whether some neurons contained
oth latent and infectious virus.
To determine whether infectious virus was present in
he TGs of vaccinated Ab
O/O mice at a later time after
hallenge, mice were vaccinated with live KOS or 7gp
nd ocularly challenged with HSV-1 as above. Sixty-three
ays after challenge, the supernatants from individually
omogenized TGs were plated on RS cells. Consistent
ith the results at 28 and 31 days postinfection, 89–100%
f the TGs from vaccinated Ab
O/O mice contained infec-
ious virus (Table 1, columns 11 and 12), while none of the
Gs from unvaccinated Ab
O/O mice (Table 1, column 10) or
accinated or unvaccinated b2m
O/O or C57BL/6J mice
ontained infectious virus. As seen at 28 and 31 days
ostinfection, at 63 days postinfection, the TGs from
nvaccinated Ab
O/O mice and vaccinated or unvaccinated
2m
O/O and C57BL/6J mice contained HSV-1 DNA, indic-
tive of latent HSV-1 (not shown).
The results of all the above experiments suggest that
egardless of the vaccine, vaccination of Ab
O/O mice prior
o ocular HSV-1 challenge resulted in the long-term pres-
nce of infectious virus in the TG, rather than in a latent
nfection. The long-term presence of infectious virus in
he absence of obvious virus-induced pathology is
ermed a chronic, productive infection or a chronic infec-
T
Chronic HSV-1 Infectio
Mice
Infectious virus in TGs 28 to 3
Naive KOS MEM gD vector
b
O/O 1/52
(2%)
35/40d
(87%)
11/16d
(69%)
20/20d
(100%)
34/34d
(100%)
2m
O/O 0/26
(0%)
0/48
(0%)
0/6
(0%)
0/20
(0%)
0/18
(0%)
57 0/39
(0%)
0/38
(0%)
0/18
(0%)
0/20
(0%)
30/30
(0%)
a Mice were vaccinated 33 with the indicated vaccine and then challe
nder Materials and Methods.
b Data were combined from two different studies.
c P , 0.01 versus unvaccinated Ab
O/O mice and versus vaccinated or
d P , 0.001 versus unvaccinated Ab
O/O mice and versus vaccinated a
e ND, not done.
The left TGs were individually freeze–thawed and ground to destroy al
ere plated on RS cells for detection of infectious virus as describedion (Ahmed et al., 1987; Jamieson and Ahmed, 1989; sarion and Robinson, 1983). This chronic infection did
ot occur in unvaccinated Ab
O/O mice.
Clearance of virus from eyes of vaccinated Ab
O/O mice.
b
O/O mice were vaccinated three times with KOS and
hen ocularly challenged with HSV-1 as described above.
ears were collected from 10 eyes/group and the pres-
nce and amount of infectious virus were determined by
laque assays on RS cells as described under Materials
nd Methods (Fig. 1). Ocular virus replication appeared
o peak on day 4 in both the vaccinated and the unvac-
inated groups. There were no differences in the amount
f virus in the tears of vaccinated compared to unvacci-
ated Ab
O/O mice at any time (P . 0.05). The percentage of
yes with virus was also the same for the two groups at
ll times (P . 0.05). After 10 days, no infectious virus
ccinated Ab
O/O Micea,b
p.i.b
Infectious virus in TGs 63
days p.i.c
7gp PBS-Adj Adj Naive KOS 7gP
8/29d
96%)
14/14d
(100%)
16/18d
(90%)
0/10 8/9
(89%)
4/4
(100%)
0/20 NDe ND 0/5 0/9 0/4
0/20 ND ND 0/10 0/12 0/10
cularly with 2 3 106 PFU of HSV-1 strain McKrae per eye as described
inated b2m
O/O and wild-type mice.
accinated b2m
O/O and C57BL/6J mice.
cells. Cell debris was removed by centrifugation, and the supernatants
Materials and Methods.
FIG. 1. Virus titers in mouse eyes following ocular challenge of mice.
aive or vaccinated Ab
O/O mice were challenged ocularly and the pres-
nce of HSV-1 in tear films was monitored daily as described under
aterials and Methods. For each bar, the virus titer (Y-axis) represents
he average of the titers from 10 eyes. The error bars indicate theABLE 1
n in Va
1 days
2
(
nged o
unvacc
nd unv
l viabletandard errors.
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211CHRONIC HSV-1 INFECTION IN Ab
O/O MICEould be detected in either group. Thus, although a
hronic infection existed in the TG of vaccinated Ab
O/O
ice for at least 63 days postinfection, the primary in-
ection appeared to have been completely cleared from
he eyes within 11 days.
The length of time between vaccination and challenge
ffects chronic infection. In mice, HSV-1 vaccines usually
roduce their strongest immune effects on the eye 3–5
eeks after vaccination, with vaccine efficacy declining
ith time (Blacklaws and Nash, 1990). To determine
hether the ability of vaccination to produce chronic
nfection in TGs would likewise fall off with time, Ab
O/O
ice were vaccinated three times with KOS as above
nd ocularly challenged with HSV-1 either 3 or 12 weeks
fter the final vaccination. The presence of infectious
irus in the TG, and hence chronic infection of the TG,
as determined 28 days after ocular challenge (Table 2,
eft). Similar to the above experiments, 90% of the TG
rom Ab
O/O mice challenged 3 weeks after vaccination
ontained infectious virus (P , 0.0001 compared to un-
accinated control group). In contrast, only 31% of the TG
rom Ab
O/O mice challenged 12 weeks after the final vac-
ination contained infectious virus. This decrease was
ighly significant (P , 0.0001) and strongly suggests that
he vaccine effect that resulted in chronic infection de-
reased with time. To confirm that the TGs not showing
nfectious virus were latently infected, the cell debris
rom some of the TG extracts was tested for the pres-
nce of HSV-1 DNA by PCR. All samples contained
SV-1 DNA (Table 2, right).
HSV-1 transcription during chronic TG infection of Ab
O/O
ice. To confirm that the infectious virus detected above
epresented an active chronic infection of the TG rather
han uncleared virus remaining from the original acute
nfection, HSV-1 transcription was examined. During la-
ency, HSV-1 transcription is limited to the LAT region
Rock et al., 1987; Wechsler et al., 1988a,b). The presence
f other HSV-1 transcription thus indicates the presence
f acute, chronic, or recurrent infection (Lynas et al.,
TABLE 2
The Length of Time between Vaccination and HSV-1 Ocular
Challenge of Ab
O/O Mice Influences Chronic Infectiona
Time between final
vaccination and
ocular challenge
Infectious virus
in TG extracts
HSV-1 DNA in pelleted
TG cell debris
weeks 27/30b (90%) 11/11 (100%)
2 weeks 10/32 (31%) 7/7 (100%)
weeks (unvaccinated) 1/14 (7%) 5/5 (100%)
a Ab
O/O mice were vaccinated 33 with KOS and challenged at the
ndicated times and the presence of infectious virus and HSV-1 DNA
as determined.
b P , 0.0001 compared to 12 weeks and unvaccinated.989). Mice were vaccinated with KOS, recombinant gD, mr vector and ocularly challenged with HSV-1 as de-
cribed above. TGs were removed 31 days after ocular
hallenge. Total RNA was isolated from individual TG
nd RT-PCR was performed to detect HSV-1 glycoprotein
(gB) mRNA as described under Materials and Meth-
ds. A gB-specific band of 190 bp was detected in the
Gs from 3 of 3 vaccinated Ab
O/O mice (Fig. 2, lanes 3, 7,
nd 11). No gB-specific RT-PCR product was detected in
Gs from unvaccinated Ab
O/O mice (lane 4), unvaccinated
2m
O/O mice (lane 5), unvaccinated C57BL/6J (lane 6),
accinated b2m
O/O mice (lanes 8 and 10), or vaccinated
57BL/6J mice (lane 9). Immunofluorescence studies
one 42 days postinfection revealed the presence of
SV-1 glycoprotein C in sections of TGs from vaccinated
b
O/O mice, but not unvaccinated Ab
O/O mice or vaccinated
r unvaccinated wild-type mice (data not shown). Thus,
he chronic infection of TGs in vaccinated Ab
O/O mice was
ssociated with continued synthesis of viral mRNAs and
roteins.
Passive transfer of HSV-1 neutralizing antibody to
hronically infected Ab
O/O mice. Due to the MHC II dele-
ion, Ab
O/O mice do not produce detectable HSV-1 neutral-
zing antibody following either HSV-1-specific vaccina-
ion or HSV-1 challenge (Ghiasi et al., 1997c). To deter-
ine whether the chronic infection in the TG of
accinated Ab
O/O mice might be related to the lack of
nti-HSV-1 antibody in these mice, we attempted to elim-
nate the infectious virus by passive transfer of anti-
SV-1 serum. Pooled serum for passive transfers was
repared from wild-type C57BL/6J mice vaccinated three
imes with HSV-1 strain KOS as described under Mate-
ials and Methods. Ab
O/O mice were vaccinated three
imes with KOS and ocularly challenged with HSV-1
train McKrae as described above. For passive transfer,
b
O/O mice were injected once intraperitoneally (ip) with
00 ml of pooled anti-HSV-1 serum either 4 h before (day
) or 28 days after ocular challenge. Forty-two days after
hallenge, TGs were examined for infectious virus (Table
FIG. 2. Detection of gB mRNA in TG of vaccinated Ab
O/O mice 42 days
fter ocular challenge. C57BL/6J, b2m
O/O, and Ab
O/O mice were vacci-
ated with expressed gD, KOS, or vector and challenged as described
nder Materials and Methods. Unvaccinated Ab
O/O mice were similarly
hallenged. RT-PCR of total RNA isolated from individual TG was
erformed as described under Materials and Methods using gB prim-
rs. Each lane shows the RT-PCR product from one TG. Lanes: (1) virus
ontrol; (2) gD vaccinated Ab
O/O mice RNA treated with RNase A; (3) gD
accinated Ab
O/O mice; (4) unvaccinated Ab
O/O mice; (5) unvaccinated
2m
O/O mice; (6) unvaccinated C57BL/6J mice; (7) KOS vaccinated Ab
O/O
ice; (8) KOS vaccinated b2m
O/O mice; (9) vector vaccinated C57BL/6J
ice; (10) vector vaccinated b mO/O mice; (11) vector vaccinated A O/O2 b
ice; and (12) virus control (no enzyme).
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212 GHIASI ET AL.). Although we previously showed that passive transfer
f anti-HSV-1 serum on the day of infection protected
gainst HSV-1-induced eye disease (Ghiasi et al., 1997a),
t did not prevent chronic infection in the TG (69% versus
0% in control, P 5 1). Passive transfer on day 28 post-
hallenge also did not alter the chronic infection (P 5 1
ersus control). Thus, passive transfer of anti-HSV-1 se-
um did not prevent or clear chronic HSV-1 infection of
he TG.
At the challenge dose used here, HSV-1 ocular chal-
enge of C57BL/6J or C57BL/6J-Ab
O/O mice does not kill
ny mice. In contrast, in BALB/c mice, which are more
ensitive to HSV-1 ocular infection, and in which approx-
mately 100% of mice die following ocular challenge with
he dose of HSV-1 used here, we previously showed that
assive transfers identical to those done here 4 h prior to
hallenge provide 100% protection against death (Ghiasi
t al., 1997b). Thus, it is unlikely that the failure of passive
ransfer to protect against chronic infection was due to
nsufficient protective antibody.
Passive transfer of anti-HSV-1 mouse sera to unvacci-
ated Ab
O/O mice. Partially as a control for the above
xperiment, unvaccinated Ab
O/O mice were injected ip with
00 ml of pooled anti-HSV-1 sera at various times before
r after ocular challenge. Chronic infection of the TG was
etermined 42 days post-ocular challenge (Table 4, mid-
le). As expected, no chronic infection was seen in any
f the 34 TG from Ab
O/O mice that received passive anti-
SV-1 serum transfers 14 days postchallenge or in any of
he 18 TG from control Ab
O/O mice that did not undergo
assive transfers (no transfer). In contrast, 28% of the TG
rom Ab
O/O mice receiving anti-HSV-1 serum 3 days prior to
cular challenge contained infectious virus (Table 4; P 5
.045 versus control). Although only 4% of the TG from
b
O/O mice receiving anti-HSV-1 serum 4 h prior to ocular
hallenge contained infectious virus (P 5 1.0 versus
ontrol), 70% of the TG from Ab
O/O mice receiving anti-
SV-1 serum on day 3 postchallenge and 72% of the TG
rom Ab
O/O mice receiving anti-HSV-1 serum on day 6
ostchallenge contained infectious virus (P , 0.0001).
TABLE 3
Passive Transfer of HSV-1 Neutralizing Antibody
to Vaccinated Ab
O/O Micea
ransfer of neutralizing antibody Infectious virus in TG extracts
Untreated 18/30 (60%)
Day 0 22/32 (69%)
Day 28 6/12 (50%)
a Ab
O/O mice were vaccinated 33 with KOS and challenged ocularly
ith HSV-1 and 300 ml of neutralizing antibody was passively trans-
erred either 4 h before ocular challenge (day 0) or 28 days postchal-
enge (day 28). The presence of infectious virus was determined 42
ays postchallenge.hus, passive transfer of anti-HSV-1 serum on days 3 orpost-ocular challenge appeared to produce chronic
nfection of the TG similar to that seen in vaccinated
ice. PCR analysis confirmed that 83% (5/6) and 100%
7/7) of the TG from the control and 14-day groups,
espectively, contained viral DNA and therefore were
atently infected (data not shown).
Passive transfer of naive mouse sera to unvaccinated
b
O/O mice. To determine whether the chronic TG infection
n Ab
O/O mice following passive transfer of anti-HSV-1
ouse sera was due to anti-HSV-1 antibody, passive
ransfers were done using pooled sera from naive mice.
assive transfer on days 3 or 6 post-ocular challenge,
ut not 4 h or 2 weeks postchallenge, again resulted in
large number of TGs containing infectious virus 42
ays postchallenge (Table 4; right; P , 0.001 for days 3
nd 6 versus 4 h, 14 days, or no passive transfer). These
esults are similar to those seen following passive trans-
er of anti-HSV-1 sera, suggesting that anti-HSV-1 anti-
ody was not responsible for the chronic infection.
Passive transfer of purified IgG. To determine whether
assive transfer of purified IgG, rather than whole sera,
lso produced chronic infection, passive transfers were
one using commercially available purified IgG. Unvac-
inated Ab
O/O mice were ocularly challenged with HSV-1
nd 3 days later received purified IgG, Fab, or Fc frag-
ents ip. TGs were examined 35 days postinfection for
he presence of infectious virus. Ab
O/O mice that received
assive transfer of purified IgG 3 days after ocular HSV-1
hallenge had high levels of chronic infection (not
hown). Surprisingly, Ab
O/O mice that received passive
ransfer of either Fab or Fc on day 3 postinfection also
ad high levels of chronic infection (not shown). These
TABLE 4
Detection of Infectious Virus in TGs Following Passive Transfer of
Serum to Unvaccinated Ab
O/O Micea
Time of passive transfer
Serum from
vaccinated miceb Naive serumc
days before challenge 5/18d (28%) ND
h before challenge 3/66 (4%) 1/16 (6%)
days after challenge 24/34d (70%) 19/20e (95%)
days after challenge 13/18d (72%) 9/14e (64%)
4 days after challenge 0/34 (0%) 1/18 (6%)
o transfer 0/18 (0%) 2/38 (5%)
a Mice were sacrificed 42 days post-ocular challenge with HSV-1 and
he presence of infectious virus in individual TG was determined
ollowing freeze–thawing, as described above. The results from two
ndependent experiments (naive serum, serum from vaccinated mice)
re shown.
b 300 ml of pooled serum from C57BL/6J mice that were vaccinated
ith HSV-1 strain KOS was transferred as above.
c Sera were collected from naive C57BL/6J mice and 300 ml of pooled
erum was passively transferred to unvaccinated Ab
O/O mice at the times
ndicated.
d P , 0.05 compared to the control; no transfer group in this column.
e P , 0.002 compared to the control; no transfer group in this column.
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213CHRONIC HSV-1 INFECTION IN Ab
O/O MICEesults suggested that the chronic infection was not the
esult of an IgG function and an additional study was
erformed for confirmation.
Passive transfer of sera from B-cell-deficient mice.
assive transfer experiments were done as described
bove, using sera from B-cell-deficient (BO/O) mice, which
ack functional B cells and antibody (Kitamura et al.,
991). Additional controls included injection of commer-
ially available purified IgG, PBS, no injection, KLH, a
rotein that induces T-cell-dependent responses, and
extran, a carbohydrate that induces type II T-cell-inde-
endent responses. All injections were given identically,
n a 300-ml volume. All of the materials, except the BO/O
era, were in PBS.
Ten Ab
O/O mice per group were ocularly challenged with
SV-1 and 3 days later received one ip injection of sera
rom BO/O mice, purified IgG, dextran, KLH, or PBS. Con-
rol mice received no injection. TG from surviving mice
ere harvested 28 days postinfection and examined for
he presence of infectious virus as above (Table 5). No
hronic infection was seen in any of the 8 TG from Ab
O/O
ice that received PBS, in any of the 18 TG from control
b
O/O mice that received no injection, or in any of the 16 TG
rom Ab
O/O mice that received dextran (Table 5). In con-
rast, 40% of the TG from Ab
O/O mice that received serum
rom BO/O mice, 50% of the TG from Ab
O/O mice that re-
eived purified IgG, and 39% of the TG from Ab
O/O mice
hat received KLH contained infectious virus (P 5 0.01,
5 0.003, and P 5 0.008, respectively, versus control;
TABLE 5
hronic Infection in TGs of Ab
O/O Mice Following Injection of Various
Substances 3 Days after Ocular Challengea
Type of treatment Infectious virus in TG extracts
Sera from BO/O miceb 4/10 (40%)
IgGc 5/10 (50%)
Dextrand 0/16 (0%)
KLHe 7/18 (39%)
PBS f 0/8 (0%)
Controlg 0/18 (0%)
a Mice were ocularly challenged with HSV-1 and 3 days later re-
eived one injection of the indicated substance. The mice were sacri-
iced 28 days post-ocular challenge and the presence of infectious
irus in individual TG was determined as described above.
b Sera were collected from naive mMT/mMT (BO/O) mice and 300 ml of
ooled serum was passively transferred to unvaccinated Ab
O/O mice 3
ays after ocular challenge.
c Ab
O/O mice received 1 mg of IgG in 300 ml of PBS 3 days after ocular
hallenge.
d Ab
O/O mice received 1 mg of a-1,6-dextran in 300 ml of PBS 3 days
fter ocular challenge.
e Ab
O/O mice received 1 mg of KLH in 300 ml of PBS 3 days after ocular
hallenge.
f Challenged Ab
O/O mice did not receive any treatment after ocular
hallenge.
g Control mice were ocularly challenged but received no injection.able 5). Thus, serum from BO/O mice, purified IgG, and cLH, but not PBS or dextran, were capable of generating
hronic infections when transferred to unvaccinated Ab
O/O
ice 3 days after ocular HSV-1 challenge.
DISCUSSION
The mechanism of HSV-1 latency (establishment and
aintenance) is not understood. However, it appears
hat the immune system plays an important role in re-
oving infectious virus from the trigeminal ganglia,
hereby allowing for a nonproductive latent infection.
cular challenge of SCID mice (which lack both T- and
-cells) with virulent strains of HSV-1 results in the death
f all mice. However, SCID mice can survive ocular
hallenge with the avirulent HSV-1 mutant in1814 (Valyi-
agy et al., 1992). When the TG of these mice were
xamined at a time at which latency was expected,
nfectious virus was found. Passive transfer of HSV-1
eutralizing antibody resulted in clearance of the infec-
ious virus from the TG and the observation of HSV-1
atent infection in many neurons. This study suggested
hat in the absence of a sufficient immune response,
SV-1 is not cleared from the TG, resulting in a chronic
roductive infection, with an underlying latent infection,
n either the same or different neurons.
In this report, we present an unusual situation. Ocular
SV-1 challenge of naive Ab
O/O mice lacking MHC-II re-
ulted in a typical latent infection in the TG. However, if
he Ab
O/O mice were vaccinated prior to ocular challenge,
he result was a chronic, rather than a latent, infection in
he TG. The type of vaccine used appeared irrelevant.
accines containing various HSV-1-specific antigens, ad-
uvant alone, or even just tissue culture medium (con-
aining 5% fetal bovine serum) all resulted in chronic
nfections. The frequency of chronic infection declined
ith increasing time between vaccination and challenge.
ince the immune response also declines with increas-
ng time after vaccination, this finding supports the no-
ion that factors induced by vaccination were involved in
he chronic infection.
Surprisingly, passive transfer of anti-HSV-1 mouse se-
um did not clear the chronic infection. Unexpectedly,
assive transfer on day 3 post-ocular challenge, of anti-
SV-1 serum, naive mouse sera, purified naive IgG, or
ven Fc or Fab fragments obtained from naive IgG, to
nvaccinated Ab
O/O mice resulted in chronic infection of
he TG similar to that seen following vaccination. Earlier
assive transfer resulted in less chronic infection. Later
assive transfer did not produce chronic infection. This
uggests that to produce chronic infection some factor
ontained in the transferred serum had to be present
arly during the acute infection, at the time of peak virus
eplication in the eye. Since passive transfer of commer-
ial-grade purified Fc and Fab resulted in chronic infec-
ion, it would appear that the mechanism producing
hronic infection was not related to a typical IgG func-
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214 GHIASI ET AL.ion. This was supported by the finding that passive
ransfer of sera from B-cell-deficient mice or injection of
LH 3 days postchallenge also resulted in high levels of
hronic infection in the Ab
O/O mice.
Chronic infection of the TG due to vaccination of Ab
O/O
ice did not appear to be related to increased virus load
n the eye. Both vaccinated and unvaccinated Ab
O/O mice
howed the same amount of HSV-1 replication in their
yes, with the same rate of viral clearance. Survival from
he acute infection was also unaltered. However, a small
ercentage (3–5%) of the chronically infected Ab
O/O mice
ied after day 28 (not shown). Since this does not occur
n mice with normal latency, it is likely that the infectious
irus in the TG of the chronically infected mice occasion-
lly made its way to the brain and caused encephalitis
ypical of the acute phase of HSV-1 infection.
In SCID mice, HSV-1 latency is altered. Ocular chal-
enge of these mice with the poorly replicating HSV-1
utant in 1814 (Preston et al., 1994) results in the con-
inued presence of infectious virus in the TGs (Gesser et
l., 1995; Valyi-Nagy et al., 1992). The most likely expla-
ation for this phenomenon is that either T-cells or B-
ells alone or both are required to clear all infectious
iruses from the TG. As reported for SCID mice, we found
hat mice deficient for both MHC-I and MHC-II (MHCO/O
ice) (Grusby et al., 1993) and mice deficient for T-cells
nude mice) (Autenrieth et al., 1993) that survived ocular
SV-1 challenge had chronic infections in their TG (not
hown). In contrast, those mice that survived ocular
SV-1 challenge and that were deficient for just MHC-I
r just MHC-II had typical latent infections of the TG, with
o apparent infectious virus. Thus, although the absence
f both MHC-I and MHC-II responses resulted in chronic
ather than latent infection, either MHC-I or MHC-II re-
ponses alone (possibly in conjunction with other im-
une responses) were sufficient for clearance of HSV-1
rom the TGs. These results thus suggest that MHC-I and
HC-II both play important roles in clearance of HSV-1
rom the trigeminal ganglia.
A possible mechanism that might account for chronic
nfection in Ab
O/O mice involves induction of NK cells
Yoshimoto et al., 1995a,b). These cells secrete large
mounts of IL-4, which might suppress viral clearance in
he absence of a normal MHC-II response. However, we
ound that NK depletion using anti-asialo GM1 antibody
Kasai et al., 1980) and NK depletion using PK136 mAb
Karlhofer and Yokoyama, 1991) did not prevent estab-
ishment of chronic infection in vaccinated Ab
O/O mice
data not shown). In fact, if anything, NK depletion re-
ulted in increased levels of infectious virus in the TG of
accinated Ab
O/O mice, since following plating of TG ex-
racts on indicator cells, HSV-1-induced cytopathic ef-
ects appeared sooner than with TG from non-NK-de-
leted vaccinated Ab
O/O mice. Macrophage depletion us-
ng Cl2MDP (Pinto et al., 1991) also did not prevent
hronic infection in vaccinated Ab
O/O mice. HNormal mouse sera, sera from B-cell-deficient mice,
urified IgG, Fc, Fab, and KLH all produced chronic
nfection when injected shortly after HSV-1 ocular chal-
enge of Ab
O/O mice. Interestingly, all of these substances
re proteins or contain proteins. In contrast, injection of
he nonprotein substances PBS and dextran did not
esult in chronic infection. The possible relevance of this
bservation remains to be determined.
Assuming that the chronic infections seen following
accination and following passive transfer of sera from
ormal or B-cell-deficient mice or injection of KLH 3 days
ostinfection are due to the same phenomenon, then
ne of two possibilities seems likely: (1) Vaccination or
njection of sera or KLH induced a factor that blocks
ormal immune clearance. Although Ab
O/O mice do not
ake T-cell-dependent IgG, T-cell-independent IgG is
ncreased by vaccination (Cosgrove et al., 1991; Grusby
nd Glimcher, 1995). (2) Vaccination or injection of sera
r KLH inhibited induction of a factor that normally me-
iates immune clearance. What this factor is and how it
esults in chronic HSV-1 infection in the TG of Ab
O/O mice
emain undetermined.
MATERIALS AND METHODS
Virus and cells. Plaque-purified HSV-1 strains were
rown in rabbit skin (RS) cell monolayers in minimal
ssential medium containing 5% fetal calf serum. McK-
ae, a stromal disease-causing, neurovirulent, HSV-1
train was the ocular challenge virus. KOS, a nonneuro-
irulent nonstromal disease-producing strain, was used
s a live virus vaccine.
Mice. Inbred C57BL/6J, C57BL/6J-nude mice and ho-
ozygous C57BL/6J-Ab
O/O, C57BL/6J-b2m
O/O, C57BL/6J-
MT/mMT (BO/O), and C57BL/6J-MHCO/O knock-out mice
Taconic, Germantown, NY; The Jackson Laboratory, Bar
arbor, ME) were used. All mice were 5 to 8 weeks old
t the start of each experiment.
Immunization. Mice were vaccinated three times sub-
utaneously (SC) with adjuvant alone, adjuvant plus PBS,
ild-type baculovirus (vector), or baculovirus recombi-
ants gD or a mixture of seven glycoproteins (gB, gC, gD,
E, gG, gH, gI) (Ghiasi et al., 1994, 1996). SC injections
ere done using Freund’s complete adjuvant on day 0
nd an identical preparation but with Freund’s incom-
lete adjuvant on days 14 and 28. Some mice were
accinated ip with 2 3 105 PFU of live KOS in tissue
ulture medium or mock-vaccinated using tissue culture
edium containing 5% FCS.
T-independent and T-dependent responses. Ab
O/O mice
ere injected with 1 mg of dextran or keyhole limpet
emocyanin in 300 ml of PBS to induce T-independent or
-dependent responses, respectively, as described pre-
iously (Cosgrove et al., 1991).
Ocular challenge. Mice were challenged ocularly with
SV-1 strain McKrae 3 weeks after vaccination using 2 3
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215CHRONIC HSV-1 INFECTION IN Ab
O/O MICE06 PFU of HSV-1 strain McKrae in 10 ml of tissue culture
edium as we previously described (Ghiasi et al., 1994).
Detection of infectious virus in trigeminal ganglia. Sur-
iving mice were euthanized and individual trigeminal
anglia were harvested and used to detect infectious or
atent virus. One TG from each mouse was individually
omogenized using an IKA Works Inc. (Wilmington, NC)
25 homogenizer at 10,000 rpm for 30 s on ice. The
ebris was removed by centrifugation at 3000 rpm for 10
in in a Beckman TA10 rotor. The supernatant was used
o infect RS-cell monolayers, which were observed daily
or the appearance of viral-induced cytopathic effect.
RT-PCR. RNA from individual trigeminal ganglia was
solated as described previously (Perng et al., 1996b).
wo gB-specific primers for first-strand (59-ATTCTCTTC-
GACGCCATATCCACCACCTT-39) and second-strand
59-AGAAAGCCCCCATTGGCCAGGTAG-39) cDNA syn-
hesis were used for RT-PCR. These primers generate a
90-bp DNA product specific for the gB nucleotides cor-
esponding to genomic nucleotides 54,640 to 54,449
McGeoch et al., 1988).
PCR analysis. Individual trigeminal ganglia were ho-
ogenized and the cell pellet was used to detect viral
NA by PCR analysis. The pellet was washed twice with
BS and the TG pellets were suspended in 100 ml of
ris–EDTA containing 0.1% SDS and 100 mg of proteinase
per milliliter. The mixture was incubated at 55°C for
6 h. The DNA was extracted and PCR was performed
sing two primers (59-CTTTGTTGAACGACACCGGGG-
GCCCTCG-39 and 59-CCACAACGGCCCGGCGCAT-
CGCTGTGGT-39) that generated a 160-bp product cor-
esponding to LAT nucleotides 471 to 631 as we de-
cribed previously (Perng et al., 1996a,b).
Passive transfer. For total antibody transfer, donor
57BL/6J mice were either vaccinated or not vaccinated
ith KOS, euthanized 3 weeks after the third vaccination,
nd bled from the vena cava. The sera from each donor
roup were combined and 300 ml of pooled sera was
hen injected ip or iv into each naive Ab
O/O recipient mouse
Ghiasi et al., 1997a,b).
For IgG, Fc, and Fab transfer, each recipient mouse
eceived an ip injection of 1 mg IgG or 0.2 mg of Fc or
ab fragments 3 days after ocular challenge. Purified
gG, Fc, and Fab molecules were purchased from Accu-
ate Chemical (Westbury, NY).
Statistical analysis. The Student t test and the Fisher
xact test were performed using the computer program
nstat (GraphPad, San Diego). Results were considered
tatistically significant when the “P” value was ,0.05.
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